AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ABBV
  • CUSIP: 00287Y10
  • Web:
  • Market Cap: $112.12863 billion
  • Outstanding Shares: 1,594,094,000
Average Prices:
  • 50 Day Moving Avg: $71.88
  • 200 Day Moving Avg: $67.01
  • 52 Week Range: $55.06 - $75.04
  • Trailing P/E Ratio: 17.32
  • Foreward P/E Ratio: 10.75
  • P/E Growth: 0.92
Sales & Book Value:
  • Annual Revenue: $26.71 billion
  • Price / Sales: 4.20
  • Book Value: $3.77 per share
  • Price / Book: 18.68
  • Annual Dividend: $2.56
  • Dividend Yield: 3.6%
  • EBIDTA: $11.57 billion
  • Net Margins: 24.77%
  • Return on Equity: 150.27%
  • Return on Assets: 12.52%
  • Debt-to-Equity Ratio: 5.63%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.25%
  • Average Volume: 5.39 million shs.
  • Beta: 1.5
  • Short Ratio: 5.37
Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, June 23rd. Investors of record on Friday, July 14th will be paid a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 annualized dividend and a yield of 3.64%. The ex-dividend date of this dividend is Wednesday, July 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has initiated a share buyback program on Sunday, April 9th 2017, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 5% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Friday, July, 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.40 by $0.02. The firm earned $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm's revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY17 earnings guidance on Friday, July, 28th. The company provided earnings per share (EPS) guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

14 analysts have issued 1-year target prices for AbbVie's stock. Their predictions range from $60.00 to $94.00. On average, they expect AbbVie's stock price to reach $74.75 in the next year. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
  • 2. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Are investors shorting AbbVie?

AbbVie saw a decrease in short interest in July. As of July 14th, there was short interest totalling 20,721,827 shares, a decrease of 15.1% from the June 30th total of 24,405,917 shares. Based on an average trading volume of 4,123,053 shares, the short-interest ratio is currently 5.0 days. Currently, 1.3% of the shares of the stock are short sold.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
  • William J. Chase, Executive Vice President, Chief Financial Officer
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
  • Carlos Alban, Executive Vice President - Commercial Operations
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
  • Timothy J. Richmond, Senior Vice President - Human Resources
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
  • Robert A. Michael, Vice President, Controller
  • Robert J. Alpern M.D., Independent Director

Who owns AbbVie stock?

AbbVie's stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (11.18%), Vanguard Group Inc. (7.28%), BlackRock Inc. (5.91%), State Street Corp (4.48%), Northern Trust Corp (1.33%) and Bank of New York Mellon Corp (1.07%). Company insiders that own AbbVie stock include Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Glenview Capital Management LLC, Bank of New York Mellon Corp, Canada Pension Plan Investment Board, AXA, APG Asset Management N.V., Prudential PLC and Strs Ohio. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Janus Henderson Group PLC, Orbis Allan Gray Ltd, Capital Research Global Investors, BlackRock Inc., Prudential Financial Inc., Balyasny Asset Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $70.42.

MarketBeat Community Rating for AbbVie (NYSE ABBV)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  555 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  851
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 6 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $74.75 (6.15% upside)

Analysts' Ratings History for AbbVie (NYSE:ABBV)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageOutperformLowView Rating Details
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$85.00LowView Rating Details
7/30/2017Cowen and CompanySet Price TargetHold$70.00LowView Rating Details
7/20/2017Credit Suisse GroupReiterated RatingNeutral$65.00 -> $74.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$65.00 -> $66.00LowView Rating Details
7/17/2017Jefferies Group LLCReiterated RatingBuy$92.00 -> $94.00LowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
6/22/2017Societe GeneraleUpgradeHold -> BuyLowView Rating Details
5/17/2017BMO Capital MarketsReiterated RatingMarket Perform$66.00LowView Rating Details
3/11/2017Goldman Sachs Group, Inc. (The)UpgradeBuy -> Conviction-Buy$74.00 -> $80.00N/AView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
8/8/2016ArgusReiterated RatingBuy$85.00N/AView Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$68.00N/AView Rating Details
6/8/2016Morgan StanleyDowngradeOverweight -> Equal Weight$73.00 -> $65.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for AbbVie (NYSE:ABBV)
Earnings by Quarter for AbbVie (NYSE:ABBV)
Earnings History by Quarter for AbbVie (NYSE ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$1.38N/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.52 EPS
Next Year EPS Consensus Estimate: $6.55 EPS


Current Dividend Information for AbbVie (NYSE:ABBV)
Most Recent Dividend:8/15/2017
Annual Dividend:$2.56
Dividend Yield:3.64%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:62.90% (Trailing 12 Months of Earnings)
46.38% (Based on This Year's Estimates)
39.08% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 67.69%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.00View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.00View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
DateHeadline logoVery Cautious On AbbVie's Fundamentals - Seeking Alpha - August 17 at 1:21 AM logoAbbVie Inc. (ABBV) Receives New Coverage from Analysts at Evercore ISI - August 16 at 6:26 PM logoKitzinger Lautmann Capital Management Inc Buys Abbott Laboratories, AbbVie Inc, Philip Morris ... - August 16 at 3:20 PM logoWhat Does AbbVie’s Dividend Curve Look Like? - August 16 at 3:19 PM logoAbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from Analysts - August 15 at 4:37 PM logoMavyret Could Amplify Gilead's HCV Pain - Seeking Alpha - August 15 at 2:24 AM logoAbbVie, Inc. – Value Analysis (NYSE:ABBV) : August 14, 2017 - August 14 at 9:20 PM logoSee what the IHS Markit Score report has to say about AbbVie Inc. - August 11 at 3:31 PM logoAbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : August 11, 2017 - August 11 at 3:31 PM logoAbbVie a Top 25 Dividend Giant With 3.56% Yield (ABBV) - August 10 at 9:50 PM logoFirst Business Financial Services, Inc. Buys iShares Russell 1000 Growth, AbbVie Inc, Aetna ... - Nasdaq - August 10 at 4:50 PM logoFirst Business Financial Services, Inc. Buys iShares Russell 1000 Growth, AbbVie Inc, Aetna ... - Nasdaq - August 10 at 4:50 PM logoCelgene’s Otezla Witnessed High Revenue Growth in 2Q17 - August 10 at 4:49 PM logoCelgene’s Otezla Witnessed High Revenue Growth in 2Q17 - August 10 at 4:49 PM logoTraders Buy High Volume of AbbVie Put Options (NYSE:ABBV) - August 10 at 7:38 AM logoGratus Capital LLC Buys AbbVie Inc, Edwards Lifesciences Corp, Sysco Corp, Sells Schwab US ... - Nasdaq - August 10 at 1:29 AM logoBiotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data - August 9 at 3:21 PM logoAbbVie Inc. (NYSE:ABBV) Chairman Sells $13,712,301.00 in Stock - August 8 at 10:28 PM logoAbbVie Wages HCV Drug-Price War on Gilead - Bloomberg Gadfly - Bloomberg - August 8 at 3:21 PM logoNCCN Foundation Announces Fifth 2017 Young Investigator Award - August 7 at 4:23 PM logoWeekly Top Insider Buys Highlight for the Week of August 4 - August 7 at 4:23 PM logoAbbVie's Mavyret Approved for Commercialization in US - August 7 at 4:23 PM logoImbruvica Could Significantly Drive AbbVie’s Revenue Growth - August 7 at 4:23 PM logoUpadacitinib: Opportunity for AbbVie’s Long-Term Growth? - August 7 at 4:23 PM logoTop 4 Marijuana Stocks to Watch for August 2017 - August 7 at 4:23 PM logoAn Update on AbbVie’s Clinical Pipeline in 2017 - August 7 at 4:23 PM logoAbbVie Inc. (ABBV) Downgraded by BidaskClub - August 6 at 1:56 PM logoThe Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games - August 6 at 10:52 AM logo Analysts Anticipate AbbVie Inc. (ABBV) Will Announce Quarterly Sales of $6.97 Billion - August 5 at 7:06 AM logoInsider Selling: AbbVie Inc. (ABBV) Chairman Sells 87,899 Shares of Stock - August 4 at 7:36 PM logoAbbVie Inc. (ABBV) CEO Richard A. Gonzalez Sells 65,861 Shares - August 4 at 7:36 PM logoAbbVie's new, cheaper hepatitis C drug could launch the drug world's own Hunger Games - MarketWatch - August 4 at 3:22 PM logoAnalysts Recommendations for AbbVie in August 2017 - August 4 at 3:22 PM logoHow Did AbbVie Perform in 2Q17? - August 4 at 3:22 PM logoNBIX: Strong Start to INGREZZA® Launch - August 4 at 3:22 PM logoHow AbbVie's 'Gauntlet' Could Squeeze Gilead's Drugs In Hepatitis C - August 4 at 3:22 PM logoAbbVie’s Humira Continues to Generate High Revenues - August 4 at 3:22 PM logo[$$] Another Price Squeeze for Drug Makers - August 4 at 3:22 PM logoAbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games - August 4 at 3:22 PM logoAbbVie Inc. (NYSE:ABBV) Expected to Post Earnings of $1.38 Per Share - August 4 at 12:16 AM logoFDA OKs new drug to treat all forms of hepatitis C - ABC News - August 3 at 9:50 PM logoFDA approves AbbVie's hepatitis C drug - August 3 at 9:50 PM logoMomenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat - August 3 at 9:50 PM logoFDA OKs new drug to treat all forms of hepatitis C - August 3 at 9:50 PM logoThe FDA Just Approved the First Drug That Can Treat All Hepatitis C Strains in Just 8 Weeks - August 3 at 9:50 PM logoAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks - August 3 at 3:38 PM logoFDA OKs AbbVie's pan-genotypic HCV med Mavyret - August 3 at 3:27 PM logoAbbVie Inc. (NYSE:ABBV) Director Buys $281,800.00 in Stock - August 2 at 8:34 PM logoSignalPoint Asset Management, LLC Buys Winnebago Industries Inc, KB Home, AbbVie Inc, Sells ... - Nasdaq - August 2 at 8:18 PM logoHenry O. Gosebruch Sells 18,000 Shares of AbbVie Inc. (ABBV) Stock - August 2 at 7:46 PM



AbbVie (ABBV) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff